The Eversense CGM System, with the first 90-day implantable sensor, received FDA approval June 2018. No real-world experience has been published.De-identified sensor glucose (SG) data from 01Aug18 to 11May19 in the Eversense Data Management System (DMS) were analyzed for the first 205 patients who reached a 90-day wear period on the Eversense CGM system. The mean SG, standard deviation (SD), median interquartile range (IQR), coefficient of variation (CV), glucose measurement index (GMI), and percent and time in minutes across glucose ranges were computed for the 24-hour time period and nighttime (0000 - 0600). Sensor accuracy, sensor reinsertion rate, transmitter wear time, and safety data were assessed.Of the 205 patients, 129 identified as type 1, 18 as type 2, and 58 were unreported. Fifty were CGM naïve, 112 had prior CGM experience, and 43 were unreported. The mean SG was 161.8 mg/dL, SD was 57.4 mg/dL, CV was 0.35 and GMI was 7.18%. Percent SG at <54 mg/dL was 1.2% (18 minutes), <70 mg/dL was 4.1% (59.7 minutes), Time in Range (≥70 to 180 mg/dL) was 62.3% (897.7 minutes), >180-250 mg/dL was 21.9% (315.8 minutes) and >250 mg/dL was 11.6% (166.7 minutes). Nighttime values were similar. The MARD (SD) using 27,708 calibration paired points against SMBG was 11.2% (11.3%). The sensor reinsertion rate was 78.5%. The median transmitter wear time was 83.6%. There were no related serious adverse events.The Eversense real-world data showed excellent glycemic results, sensor accuracy, and safety. These data suggest that the Eversense CGM system is a valuable tool for diabetes management.